DOCSLIB.ORG

Stichtag 01.12.2019 1 Von

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stichtag 01.12.2019 1 Von Transparenz in der Forschung Medizinische Hochschule Hannover Projektförderung - Stichtag 01.12.2019 Lfd.-Nr. Hoch- Organisationseinheit Förderung/Auftraggeber Projekttitel Laufzeit Gesamtfördersumme schule 1 MHH Allgemeinmedizin Diakonisches Werk evangelischer Kirchen in Implementierung von Hospizkultur und Palliativkompetenz in 2019-2021 396.752,08 € Niedersachsen e. V. Altenpflegeeinrichtungen der Diakonie Niedersachsen 2 MHH Allgemeinmedizin Innovationsausschuss beim Gemeinsamer Novelle- Sektorenübergreifendes & integriertes Notfall- und 2019-2023 199.501,00 € Bundesauschuss Verfügungsmanagement für die letzte Lebensphase in stationärer Langzeitpflege - FKZ 01NVF18007 3 MHH Allgemeinmedizin Innovationsausschuss beim Gemeinsamer KOPAL - Entwicklung und Evaluation eines Konzeptes zur 2019-2022 258.308,06 € Bundesauschuss berufsübergreifenden Zusammenarbeit bei Patienten mit palliativen Versorgungsbedarf - FKZ 01VSF18024 4 MHH Allgemeinmedizin Innovationsausschuss beim Gemeinsamer OPAL - Optimale Versorgung am Lebensende - FKZ 01VSF17028 2018-2021 693.062,38 € Bundesauschuss 5 MHH Allgemeinmedizin Universitätsklinikum Düsseldorf COFRAIL - Familienkonferenzen bei Frailty: Erhöhung der Patientensicherheit 2018-2021 112.950,00 € durch gemeinsame Priorisierung - FKZ 01VSF17053 6 MHH Allgemeinmedizin Universitätsmedizin Göttingen Einrichtung eines Kompetenzzentrums Weiterbildung in der 2018-2022 209.712,00 € Allgemeinmedizin für Niedersachsen 7 MHH Allgemeinmedizin Universität Leipzig AgeWell.de - Datenmanagement, Qualitätssicherung und Biometrie. 2017-2021 79.737,35 € 8 MHH Allgemeinmedizin Deutsches Zentrum für Luft- und Raumfahrt - Dy@Eol - Interaktion am Lebensende in Dyaden von Eltern und erwachsenen 2017-2020 387.984,00 € DLR Projekträger Kindern - FKZ 01GY1711 9 MHH Allgemeinmedizin Deutsches Zentrum für Luft- und Raumfahrt - ProPall -Proaktive Palliativversorgung älterer Patienten in der letzten 2017-2020 475.981,20 € DLR Projekträger Lebensphase - FKZ 01GY1710 10 MHH Allgemeinmedizin Deutsches Zentrum für Luft- und Raumfahrt - AgeDifferent.de - Eine theoriebasierte Analyse geschlechtsspezifischer 2017-2020 59.419,20 € DLR Projekträger Entwicklungspfade (Trajektorien) für gesundes Altern auf der Grundlage einer gemeinsamen analytischen Plattform prospektiver Kohortendaten hochaltriger Menschen, Teilprojekt 4 - FKZ 01 11 MHH Allgemeinmedizin Innovationsausschuss beim Gemeinsamer HiOPP-3-iTBX-Angemessene und sichere Medikation für 2017-2020 1.776.566,70 € Bundesauschuss Heimbewohner/innen mit Hilfe einer interprofessionellen Toolbox (AMTS- Toolbox) - FKZ 01VSF16017 12 MHH Allgemeinmedizin Ludwig-Maximilians Universität München ACD-Accountable Care in Deutschland - Verbesserung der 2017-2020 122.991,25 € (LMU) Patientenversorgung durch Vernetzung von Leistungserbringern und informierten Dialog - FKZ 01VSF16046 13 MHH Allgemeinmedizin Deutsches Zentrum für Luft- und Raumfahrt - Allgemeine ambulante Palliativversorgung in der hausärztlichen Praxis 2016-2021 897.045,60 € DLR Projekträger (ALLPRAX) – FKZ 01GY1610 14 MHH Allgemeinmedizin DFG Deutsche Forschungsgemeinschaft Das Absetzen von Medikamenten bei älteren Patienten mit Polypharmazie in 2016-2020 180.578,00 € der hausärztlichen Versorgung: Entwicklung einer komplexen Intervention - FKZ JU2992/2-1 1 von 130 Transparenz in der Forschung Medizinische Hochschule Hannover Projektförderung - Stichtag 01.12.2019 15 MHH Anästhesiologie und CSL Behring GmbH Einfluss von Fibrinogen auf postoperative Blutungen bei Kindern, die sich ei- 2019-2019 12.302,93 € Intensivmedizin ner herzchirurgischen Operation mit kardiopulmonalem Bypass unterziehen . 16 MHH Anästhesiologie und Universitätsklinikum Heidelberg Next-Generation Sequencing diagnistics of becteremia in sepsis (Next 2019-2021 3.150,56 € Intensivmedizin GeneSiS-Trail) 17 MHH Anästhesiologie und Universitätsklinikum Aachen, Aör iHope-Studie 2018-2020 45.333,62 € Intensivmedizin 18 MHH Anästhesiologie und Drägerwerk AG & Co. KGaA Assessment of the capability of Pulmovista 500 to contibousloy monitor 2017-2019 28.503,55 € Intensivmedizin changes of ventilation over time 19 MHH Anästhesiologie und Grünenthal GmbH Unverblindete Sicherheitsstudie zu intravenös angewendeter Neridronsäure 2017-2020 68.844,78 € Intensivmedizin bei Patienten mit komplexem regionalen Schmerzsyndrom (CRPS) "KF7013- 03" 20 MHH Anästhesiologie und Gesellschaft der Freunde der Medizinischen Intensiv-Monitoring 2016-2021 239.920,00 € Intensivmedizin Hochschule Hannover e.V. 21 MHH Anästhesiologie und B. Braun-Stiftung Gelatine bei Kindern 2015-2020 21.350,15 € Intensivmedizin 22 MHH Anästhesiologie und Förderstiftung MHHplus Patient Blood Management 2014-2022 14.920,00 € Intensivmedizin 23 MHH Anästhesiologie und B. Braun-Stiftung Evaluation des Managements von ambulanten Medikamenten für die 2014-2022 15.000,00 € Intensivmedizin Anästhesie in der perioperativen Phase (EMMAperiop) 24 MHH Anästhesiologie und Förderstiftung MHHplus Der Einsatz der Fluoreszenoptischen Handscanner-Untersuchung (Xiralite) 2013-2022 7.473,50 € Intensivmedizin bei CRPS 25 MHH Arbeitsbereich Klinische Niedersächsische Landesamt für Soziales, Prävention sexuellen Kindesmissbrauchs für noch nicht straffällig gewordene 2019-2020 70.000,00 € Psychologie und Sexualmedizin Jugend und Familie Pädophile ( Präventionsprojekt Dunkelfeld) 26 MHH Arbeitsbereich Klinische Niedersächsische Landesamt für Soziales, Prävention und Behandlung dysregulierten Sexualverhaltens 2019-2022 90.400,00 € Psychologie und Sexualmedizin Jugend und Familie 27 MHH Arbeitsbereich Klinische DFG Deutsche Forschungsgemeinschaft Fit im Kopf durch Musizieren: Eine Untersuchung zu den Auswirkungen von 2018-2021 213.414,60 € Psychologie und Sexualmedizin Musikunterricht auf Denken, Lebensqualität und Hirnplastizität 28 MHH Arbeitsbereich Klinische DFG Deutsche Forschungsgemeinschaft Botulinumtoxin A Behandlung der Borderline-Persönlichkeitsstörung: 2018-2020 161.860,00 € Psychologie und Sexualmedizin Neuronale Grundlagen von Emotionsverarbeitung und Impulskontrolle (BTX- BPS) 29 MHH Arbeitsbereich Klinische GKV-Spitzenverband Behandlung von Patienten mit pädophilen Sexualstörungen 2018-2022 1.861.182,16 € Psychologie und Sexualmedizin 2 von 130 Transparenz in der Forschung Medizinische Hochschule Hannover Projektförderung - Stichtag 01.12.2019 30 MHH Arbeitsbereich Klinische European Society for Sexual Medicine RG15-20: Sex Addiction in men: Clinical charcterization and alterations of 2016-2020 27.900,00 € Psychologie und Sexualmedizin Brain structure and Function (Sex@Brain-Study) 31 MHH Arbeitsbereich Klinische Förderstiftung MHHplus Projekt "Dunkelfeld" 2013-2022 33.710,00 € Psychologie und Sexualmedizin 32 MHH Augenheilkunde Novartis Pharma GmbH An Eighteen-Month, Two-Arm, Randomized, Double- Masked, Multicenter, 2019-2025 94.591,66 € Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlu 33 MHH Augenheilkunde Roche Pharma AG A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator 2019-2022 156.601,16 € Controlled Study to Evaluate the efficacy and safety of FARICIMAB in Patients with neovascular age-related macular degeneration GR40844, (LUCERNE) 34 MHH Augenheilkunde Novartis Pharma GmbH A randomized, active-controlled, patient and investigatormasked, multiple 2019-2020 57.354,71 € dose proof -of-concept study of intravitreal LK651 in patients with diabetic macular edema 35 MHH Augenheilkunde Chengdu Kanghong Biotechnology Co. A Multicenter, Double-Maske, Randomized, Dose-Ranging Trial to Evaluate 2019-2024 94.414,49 € the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration. 36 MHH Augenheilkunde Bundesministerium für Wirtschaft und Patientenadaptives Drucküberwachungs- und Behandlungssystem zur 2018-2020 189.169,00 € Energie- Zentrales Innovationsprogramm Glaukomtherapie, Laborexperimentelle Evaluation von Ansätzen zur Fibrose- Mittelstand und Vernarbungshemmung und Implantation der Prototypen 37 MHH Augenheilkunde Roche Pharma AG A Phase III, Multicenter, Randomized, Double-Masked, active Compartor 2018-2022 159.086,01 € Controlled study to evaluate the efficacy and safety of RO6867461 in Patients with diabetic macular edema ( YOSEMITE) GR40349 38 MHH Augenheilkunde Bayer Pharma AG A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat 2017-2021 55.271,14 € and Extend regimen of intravitreal afibercept for treatment of macular edema secondary to central retinal vein occlusion. CENTERA 39 MHH Augenheilkunde Roche Pharma AG A multicenter, open-label extension study to evaluate the long-term safety 2017-2020 94.310,91 € and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a Roche-sponosred study (GX30191, OMASPECT) 3 von 130 Transparenz in der Forschung Medizinische Hochschule Hannover Projektförderung - Stichtag 01.12.2019 40 MHH Augenheilkunde Novartis Pharma GmbH RAINBOW Extension study: an extension study to evaluate the long term 2016-2025 18.986,54 € efficacy and safety of RAnibizumab compared with laser therapy fro the treatment of INfants Born prematurely With retinopathy of prematurity 41 MHH Augenheilkunde TFS Trial Form Support GmbH Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to 2016-2019 78.238,73 € Lucentis in patients with neovascular age-related macular degeneration
Load more

Recommended publications
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • Chemosaturation with Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases Evan S
    Special Report Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases Evan S. Glazer, MD, PhD, and Jonathan S. Zager, MD Background: In patients with hepatic metastases from solid-organ malignancies, surgical resection may be a potentially curative option, but it is not possible in most cases. Chemosaturation with percutaneous hepatic perfusion was developed for the management of unresectable metastases to the liver. Methods: Relevant medical literature was summarized with regard to the outcomes and limitations of che- mosaturation with percutaneous hepatic perfusion. Results: Six articles were identified that contained data on 91 individuals who received chemosaturation with percutaneous hepatic perfusion. More than 60% of these study patients were diagnosed with ocular melanoma. The overall response rate was 48% and the rate of disease control was 90%. Chemosaturation with percutaneous hepatic perfusion improved the rates of overall and hepatic progression-free survival (PFS). The data are limited but suggest that the rate of PFS was improved in study patients with isolated melanoma hepatic metastases who received chemosaturation with percutaneous hepatic perfusion compared with those assigned to standard care. Conclusions: Our results suggest that chemosaturation with percutaneous hepatic perfusion produces favor- able tumor response rates in select individuals with unresectable hepatic metastases from multiple primary cancers, particularly ocular and cutaneous melanomas. Data from a single randomized
    [Show full text]
  • Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results
    Source: Delcath Systems, Inc. July 28, 2021 09:00 ET Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: August 10, 2021 Time: 8:30 AM Eastern Time Toll Free: 877-545-0523; Entry Code: 148562 International: 973-528-0016; Entry Code: 148562 The call will also be available over the Internet and accessible at: https://www.webcaster4.com/Webcast/Page/2475/42376 About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA). In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Delcath Systems, Inc
    Delcath Systems, Inc. Corporate Presentation (NASDAQ: DCTH) August 2020 Forward-looking Statements This presentation contains forward-looking statements, which are subject to certain risksand uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company’s clinical trials including without limitation the OM and ICC clinical trial programs, timely enrollment and treatment of patients in the global Phase 3 OM and ICC Registration trials, IRB or ethics committee clearance of the Phase 3 OM and ICC Registration trial protocols from participating sites andthe timing of site activation and subject enrollment in each trial, the impact of the presentations at major medical conferences and future clinical results consistent with the data presented, the Company’s ability to successfully commercialize the Melphalan HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the impact of the Company’s exclusive licensing agreement with medac on commercial adoption in Europe and resulting revenue, if any, the Company’s ability to successfully enter into other strategic partnerships and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities.
    [Show full text]
  • Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, And
    ANTICANCER RESEARCH 33: 1989-2000 (2013) Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, and Gastric Cancer Cell Lines in a Short-term Exposure Model of Chemosaturation Therapy by Percutaneous Hepatic Perfusion RAJNEESH P. UZGARE, TIMOTHY P. SHEETS and DANIEL S. JOHNSTON Pharmaceutical Research and Development, Delcath Systems, Inc., Queensbury, NY, U.S.A. Abstract. Background: The goal of this study was to candidates for use in the CS-PHP system to treat patients determine whether liver, gastric, or colonic cancer may be with gastric and colonic metastases, and primary cancer of suitable targets for chemosaturation therapy with the liver. percutaneous hepatic perfusion (CS-PHP) and to assess the feasibility of utilizing other cytotoxic agents besides Chemotherapeutic molecules exert beneficial clinical effects melphalan in the CS-PHP system. Materials and Methods: by inhibiting cell growth or by inducing cell death via Forty human cell lines were screened against three cytotoxic apoptosis. They can be divided into several categories based chemotherapeutic agents. Specifically, the dose-dependent on their mechanisms of action. The chemotherapeutic agent effect of melphalan, oxaliplatin, and paclitaxel on melphalan hydrochloride, which has been approved by the proliferation and apoptosis in each cell line was evaluated. US Food and Drug Administration and is used in the These agents were also evaluated for their ability to induce treatment of multiple myeloma and ovarian cancer, is a apoptosis in normal primary human hepatocytes. A high- derivative of nitrogen mustard that acts as a bifunctional dose short-term drug exposure protocol was employed to alkylating agent. Melphalan causes the alkylation of DNA at simulate conditions encountered during CS-PHP.
    [Show full text]
  • Core Messages
    1 DELCATH SYSTEMS, INC CHEMOSAT® 2 DELCATH SYSTEMS, INC CHEMOSAT® 3 DELCATH SYSTEMS, INC CHEMOSAT® University of Maryland-Baltimore 4 DELCATH SYSTEMS, INC CHEMOSAT® Unresectable cancers (primary or metastatic) confined to liver are a significant clinical problem: Colorectal cancer: 35,000/yr HCC/cholangiocarcinoma: 20,500/yr Ocular melanoma: 2,500/yr Neuroendocrine tumors: 3,000/yr Other histologies Therapeutic options are limited and survival after diagnosis of diffuse liver metastases is short. Morbidity and mortality in this setting is most frequently a consequence of disease progression in the liver. Effective control of isolated diffuse metastases to the liver is a significant clinical challenge 5 DELCATH SYSTEMS, INC CHEMOSAT® Intra-arterial delivery of therapeutic agents (versus portal venous system) will be preferentially delivered to metastases Dose escalation of therapeutic agents is possible Normal tissue tolerance of the perfused organ is higher Infused agent should have a broad non-specific mechanism of action Melphalan has a broad spectrum of activity with dose levels achieved during PHP Control of systemic exposure is possible First pass effect (FUDR) Sequestration in the liver (TACE, SIRS) Physical isolation Filtration Systemic toxicities can be easily diagnosed and managed; comparable to the toxicities seen with commonly used systemic chemotherapeutic agents Potentially provides treatment to the entire organ Provides opportunity to use novel agents 6 DELCATH SYSTEMS, INC CHEMOSAT® Old Linear Model
    [Show full text]
  • Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: a Prospective Phase II Study
    Ann Surg Oncol https://doi.org/10.1245/s10434-020-08741-x ORIGINAL ARTICLE – PERITONEAL SURFACE MALIGNANCY Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study T. Susanna Meijer, MD1 , Mark C. Burgmans, MD, PhD1, Eleonora M. de Leede, MD2, Lioe-Fee de Geus-Oei, MD, PhD1,3, Bas Boekestijn, MD1, Henricus J. M. Handgraaf, MD, PhD2, Denise E. Hilling, MD, PhD2, Jacob Lutjeboer1, Jaap Vuijk, MD, PhD4, Christian H. Martini, MD, PhD4, Arian R. van Erkel, MD, PhD1, Rutger W. van der Meer, MD, PhD1, Fred G. J. Tijl5, Frank M. Speetjens, MD, PhD6, Ellen Kapiteijn, MD, PhD6, and Alexander L. Vahrmeijer, MD, PhD2 1Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; 3Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands; 4Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; 5Department of Extra Corporal Circulation, Leiden University Medical Center, Leiden, The Netherlands; 6Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands ABSTRACT (BOR). Secondary endpoints included overall survival Background. Ocular melanoma is the most common pri- (OS), progression-free survival (PFS), hepatic PFS (hPFS), mary intraocular malignancy and has a very poor prognosis and safety. once liver metastases occur. Theaim of this study was to Results. Sixty-four M-PHP procedures were performed in prospectively assess the efficacy and safety of percutaneous 35 patients between February 2014 and June 2017. The hepatic perfusion with melphalan (M-PHP) using the new ORR was 72%.
    [Show full text]
  • View Annual Report
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2009 o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ____________ to ____________ Commission file number: 001-16133 DELCATH SYSTEMS, INC. Delaware 06-1245881 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 600 Fifth Avenue, 23rd Floor, New York, NY 10020 (Address of principal executive offices) (Zip Code) 212-489-2100 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, par value $0.01 per share The NASDAQ Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes o No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes o No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • ( 12 ) United States Patent
    US010233174B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,233 , 174 B2 Long ( 45) Date of Patent : Mar. 19 , 2019 ( 54 ) THIOCARBAMATE PRODRUGS OF FOREIGN PATENT DOCUMENTS TOFACITINIB CN 106496233 A 3 /2017 WO 93 /22334 Al 11/ 1993 (71 ) Applicant : THERAVANCE BIOPHARMA R & D wo 2011 /097987 A1 8 / 2011 IP , LLC , South San Francisco , CA WO 2011097087 AL 8 / 2011 (US ) OTHER PUBLICATIONS ( 72 ) Inventor: Daniel D . Long , San Francisco , CA Amidon et al ., " Colon - targeted oral drug delivery systems: Design (US ) trends and approaches ” , AAPS PharmSciTech , 16 ( 4 ) : 731 - 741 ( 2015 ) . (73 ) Assignee : THERAVANCE BIOPHARMA R & D Azad Khan et al. , “ Tissue and bacterial splitting of sulphasalazine ” , IP , LLC , South San Francisco , CA Clinical Science, 64 : 349 - 354 ( 1983 ) . Bouvier et al. , “ First enzymatically activated Taxotere prodrugs (US ) designed for ADEPT and PMT” , Bioorganic & Medicinal Chem istry , 12 : 969 -977 (2004 ) . ( * ) Notice: Subject to any disclaimer, the term of this Bunnelle , “ Reagents for stereoselective preparation of N - carbamyl patent is extended or adjusted under 35 beta - D - glucuronides ” , The Journal of Organic Chemistry , 76 : 5429 5432 ( 2011 ) . U . S . C . 154 ( b ) by 0 days . Burke et al. , “ Development of novel quaternary ammonium linkers for antibody -drug conjugates ” , Molecular Cancer Therapeutics, (21 ) Appl. No. : 15 / 986 ,018 15 ( 5 ) : 938 - 945 (May 2016 ) . Chourasia et al. , “ Pharmaceutical approaches to colon targeted drug delivery systems” , J Pharm Pharmaceut Sci, 6 ( 1 ) : 33 -66 (2003 ) . ( 22) Filed : May 22 , 2018 Clark et al. , “ Discovery and development of Janus Kinase (JAK ) inhibitors for inflammatory diseases ” , Journal of Medicinal Chem istry , 57 : 5023 - 5038 ( 2014 ) .
    [Show full text]
  • Paediatric Committee (PDCO) Draft Agenda for the Meeting on 28-31 January 2020
    28 January 2020 EMA/PDCO/3481/2020 Inspections, Human Medicines Pharmacovigilance and Committees Division Paediatric Committee (PDCO) Draft agenda for the meeting on 28-31 January 2020 Chair: Koenraad Norga – Vice-Chair: Sabine Scherer 28 January 2020, 14:00- 19:00, room 2C 29 January 2020, 08:30- 19:00, room 2C 30 January 2020, 08:30- 19:00, room 2C 31 January 2020, 08:30- 13:00, room 2C Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
    [Show full text]
  • Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting April 30, 2021 A Presentation of Positive Preliminary Efficacy Results from the FOCUS Phase III trial Company Q&A Webinar Scheduled for Monday, June 7, 2021 at 8:30am ET NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually June 4-8, 2021, and announced a company Q&A webinar has been scheduled for Monday, June 7, 2021 at 8:30am ET. ASCO Presentation Details: Title: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial. Type: Oral Abstract Presentation Track: Melanoma/Skin Cancers Presenter: Jonathan S. Zager, MD FACS Abstract Number: 9510 Date and Time: Available Starting June 4, 2021, 9:00 AM (EDT) Dr. Zager will be presenting on behalf of the Principal Investigators that participated in the FOCUS trial. The full ASCO meeting program is available at: www.asco.org. Q&A Webinar Details: The company invites investors to join a Q&A webinar on June 7 at 8:30am ET, hosted by Gerard Michel, CEO. Mr. Michel will introduce the company and its strategy, as well as discuss the positive preliminary results from its Phase 3 FOCUS Trial of HEPZATO in patients with metastatic ocular melanoma. Management will also provide answers on the live call to any questions submitted by attendees.
    [Show full text]